Skip to main content

Table 1 Patient information

From: Metabolomics reveals distinct, antibody-independent, molecular signatures of MS, AQP4-antibody and MOG-antibody disease

  RRMS AQP4-Ab NMOSD MOG-Ab
Number of patients 34 54 20
Age, mean (range), y 41 (18–60) 53 (22–83)*† 39 (16–70)
Gender, No. female (% female) 25 (74) 46 (85) 9 (45)
EDSS, median (range) 4 (0–7) 3 (0–8) 2 (0–8)
Disease duration, median (range), months 89 (1–301) 70 (3–270) 16 (1–420)*~
Time since relapse, median (range), months 23 (0–133) 22 (0–108) 8 (1–39)*~
On oral prednisolone, % 0% 85% 35%
On prednisolone, mean dose mg 0 12 14
On azathioprine, % 0 49 5
On methotrexate, % 0 11 5
On mycophenolate, % 0 19 5
On interferon β, % 15 0 5
On glatiramer, % 12 0 0
On fingolimod, % 12 0 0
On dimethyl fumarate, % 12 3 0
On natalizumab, % 15 0 0
  1. The Kolmogorov-Smirnov test was used to identify significant differences of each class compared to RRMS (*), AQP4-Ab NMOSD (~), or MOG-Ab disease (†)